Levetiracetam Should NOT Be Withheld for Orthopedic Surgery
Continue levetiracetam perioperatively in this patient with a 12-year history of seizure disorder undergoing orthopedic surgery. Abrupt discontinuation of antiepileptic drugs increases the risk of breakthrough seizures and status epilepticus, which would pose far greater perioperative risks than continuing the medication 1.
Rationale for Continuation
Risk of Withdrawal Seizures
The FDA label explicitly warns that "antiepileptic drugs, including levetiracetam, should be withdrawn gradually to minimize the potential of increased seizure frequency" 1. Perioperative stress, metabolic changes, and altered drug absorption already increase seizure risk—discontinuing levetiracetam would compound this danger significantly.
Favorable Perioperative Safety Profile
Levetiracetam demonstrates excellent tolerability in surgical settings:
- Minimal cardiovascular effects: Unlike phenytoin (which causes hemodynamic instability with IV loading), levetiracetam has no significant intraoperative cardiovascular complications 2
- No drug interactions: Levetiracetam lacks the cytochrome P450 interactions that complicate anesthetic management with older antiepileptics 3
- Proven perioperative safety: A 2013 prospective randomized study in craniotomy patients found levetiracetam well-tolerated perioperatively with no significant discontinuations due to side effects (1/36 patients) 2
Superior Recovery Outcomes
Recent evidence from 2026 shows levetiracetam offers perioperative advantages 4:
- Significantly reduced delayed emergence (7% vs 19% with phenytoin, p=0.012)
- Shorter recovery time (34.5 vs 51.4 minutes)
- Shorter hospital stay (2.95 vs 4.83 days)
Practical Management Algorithm
Preoperative (Day Before Surgery):
- Verify patient took morning dose of levetiracetam
- Document seizure-free interval (longer seizure-free periods correlate with better perioperative outcomes 4)
- Ensure IV access plan if NPO status prolonged
Day of Surgery:
- Administer morning dose with small sip of water (standard practice for antiepileptics)
- If NPO >12 hours or concerns about oral absorption, consider IV levetiracetam at same dose (bioavailability equivalent)
Postoperative:
- Resume oral levetiracetam as soon as patient tolerates PO intake
- If prolonged NPO anticipated, use IV formulation (well-tolerated, no dose adjustment needed 2)
- Monitor for 24 hours postoperatively (highest risk period for breakthrough seizures 4)
Important Caveats
Renal Function Considerations
If the patient has renal impairment, verify appropriate dose adjustment preoperatively, as levetiracetam clearance is renally dependent 3, 5. Orthopedic surgery may involve perioperative fluid shifts affecting renal function.
Behavioral Monitoring
While rare, levetiracetam can cause behavioral adverse effects (irritability, mood changes) in 5-12% of patients 1. These are typically mild and should not preclude perioperative use, but postoperative delirium screening should account for this.
Drug Level Monitoring Not Required
Routine therapeutic drug monitoring is unnecessary for levetiracetam given its predictable pharmacokinetics and broad therapeutic window 3. Focus instead on clinical seizure control.
Why Withholding Would Be Harmful
Discontinuing levetiracetam creates multiple risks:
- Breakthrough seizures: Perioperative seizures complicate anesthetic management and increase aspiration risk
- Status epilepticus: Can occur with abrupt AED withdrawal, carrying 10-20% mortality
- Prolonged hospitalization: Seizures would necessitate ICU monitoring and delay rehabilitation
- Orthopedic complications: Seizure-related movements could compromise surgical repair
The evidence unequivocally supports continuing levetiracetam throughout the perioperative period for this patient.